Evidence map›Paper›PMID 36301267›Full record

ArticleCancer immunology research2023

Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells.

Patrick K Juras, Luigi Racioppi, Debarati Mukherjee, Sandeep Artham, Xia Gao, Laura Akullian D'Agostino, Ching-Yi Chang, Donald P McDonnell

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Patrick K JurasDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0003-2999-0565
Luigi RacioppiDepartment of Medicine, Division of Hematological Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-9207-6752
Debarati MukherjeeDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0003-2674-174X
Sandeep ArthamDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-0556-8979
Xia GaoDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0003-0979-9990
Laura Akullian D'AgostinoSmall Molecule Drug Discovery, Bristol Myers Squibb, Cambridge, Massachusetts.ORCID 0000-0002-8218-1428
Ching-Yi ChangDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0003-2115-9574
Donald P McDonnellDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-7331-4700
Duke University · USBristol-Myers Squibb (United States) · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
Understanding methionine metabolism and its therapeutic potential in cancerR00CA237618 · NCI · BAYLOR COLLEGE OF MEDICINE · PI GAO, XIA · 2022 to 2024
$747k
Understanding methionine metabolism and its therapeutic potential in cancerK99CA237618 · NCI · DUKE UNIVERSITY · PI GAO, XIA · 2019 to 2020
$192k
The role of CaMKK2 in tumor-infiltrating natural killer cellsF30CA261005 · NCI · DUKE UNIVERSITY · PI JURAS, PATRICK · 2021 to 2022
$82k
NCI NIH HHS F30 CA261005NCI NIH HHS K99 CA237618NCI NIH HHS P30 CA014236NCI NIH HHS R00 CA237618
6 · The paper itself

Abstract

Calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) is a key regulator of energy homeostasis in several cell types. Expression of this enzyme in tumor cells promotes proliferation and migration, and expression in tumor-associated immune cells facilitates M2 macrophage polarization and the development of myeloid-derived suppressor cells. Thus, there has been interest in developing CaMKK2 inhibitors as potential anticancer therapeutics. One impediment to clinical development of these agents is that the roles of CaMKK2 in other cellular compartments within the tumor immune microenvironment remain to be established. We report herein that CaMKK2 is expressed at low basal levels in natural killer (NK) cells but is upregulated in tumor-infiltrating NK cells where it suppresses apoptosis and promotes proliferation. NK cell-intrinsic deletion of CaMKK2 increased metastatic progression in several murine models, establishing a critical role for this enzyme in NK cell-mediated antitumor immunity. Ablation of the CaMKK2 protein, but not inhibition of its kinase activity, resulted in decreased NK-cell survival. These results indicate an important scaffolding function for CaMKK2 in NK cells and suggest that competitive CaMKK2 inhibitors and ligand-directed degraders (LDD) are likely to have distinct therapeutic utilities. Finally, we determined that intracellular lactic acid is a key driver of CaMKK2 expression, suggesting that upregulated expression of this enzyme is an adaptive mechanism by which tumor-infiltrating NK cells mitigate the deleterious effects of a lactic acid-rich tumor microenvironment. The findings of this study should inform strategies to manipulate the CaMKK2-signaling axis as a therapeutic approach in cancer.

Indexed as

NeoplasmsAnimalsApoptosisCalcium-Calmodulin-Dependent Protein Kinase KinaseHumansMacrophagesMicePhosphorylationSignal TransductionTumor MicroenvironmentCalcium-Calmodulin-Dependent Protein Kinase KinaseCAMKK2 protein, humanCamkk2 protein, mouse

Identifiers

PMID36301267
PMCPMC9812906
OpenAlexW4307427839

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.